Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

In general, UBS expects Eli Lilly’s quarterly sales to exceed expectations by 2%. According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly’s blockbuster GLP-1 drugs dominate headlines, but its broader portfolio deserves a standing ovation for driving ...

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly’s Mounjaro launch SA NewsTue, Jun. 24 4 Comments ...